Companion Diagnostics – a Burgeoning Market

Since the first drug requiring a companion diagnostic test was approved by the U.S. Food and Drug Administration (FDA) in 1998, the global market for companion tests has exploded to $1.8 billion in 2012 and is projected to triple to $5.6 billion by 2019, according to a report by Transparency Market Research. “Companion diagnostics are an indispensable part of personalized medicine and will likely continue to rapidly increase in number and application to disease areas,” says Amit Agarwal and colleagues in a study of the future of companion diagnostics, published
in the Journal of Pharmacogenomics and Personalized Medicine last year.